pharmaphorum · Jun 2026
Summarizes the financing and notes the earlier $40M Series A and $130M Series B plus the company’s path toward the clinic.
Epigenetic reprogramming to treat age-related diseases.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
NewLimit is a South San Francisco biotechnology company building AI- and genomics-driven epigenetic reprogramming medicines to restore youthful function in old cells and extend human healthspan; its lead liver program is moving toward first-in-human studies.
Primary product
Epigenetic reprogramming medicines for aging-related disease, led by a liver-targeted mRNA/LNP reprogramming therapy
Founded
2022
Headquarters
South San Francisco, California, United States
Team size
40-50
Industry
Biotechnology Research
Sub-industry
Epigenetic reprogramming therapeutics
Offices
South San Francisco, California, United States
Open Positions
15 jobs at NewLimit
Scientist, Drug Product Development
On-siteDelivery SciencesSouth San FranciscoToday
On-site